Ping Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ping Zhou has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Cheng Chen
Department of Neonatology, Longgang District Maternity & Child Healthcare Hospital of Shenzhen City (Longgang Maternity and Child Institute of Shantou University Medical College), China
3 shared publications Lian Zhang
Department of Neonatology, Baoan Women’s and Children’s Hospital
3 shared publicationsQin Tang
Department of Neonatology, Baoan Women's and Children's Hospital
3 shared publications- Dan Dan Rao
Neonatology, Shenzhen Luohu Hospital Group Luohu People's Hospital, Shenzhen, Guangdong, China
2 shared publications Dingding Yin
Department of Neonatology, Baoan Women's and Children's Hospital
2 shared publicationsFangmei Luo
Department of Neonatology, Guangdong Women and Children Hospital, Guangzhou, China
2 shared publications
Latest Publications
- Open Access
- 4 November 2026
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 14, 1728536
Nonlinear evolution of acoustic characteristics of bowel sounds in preterm infants
Introduction: Gastrointestinal function can be assessed through bowel sounds, which objectively indicate gastrointestinal movement. However, the conventional method of abdominal auscultation has considerable limitations. This study aimed to investigate the evolutionary patterns of acoustic characteristics of bowel sounds in preterm infants, explore their variation with postmenstrual ages (PMAs), and quantify the association between PMA and bowel sound maturity to characterize the developmental trajectory of intestinal motility in preterm infants. Methods: Twenty-seven preterm infants (gestational age: 30–36 + 6 weeks) were enrolled in this study. A convolutional neural network-based smart device was used to monitor bowel sounds 1–4 times weekly for ≥3 h from day 1 to 30 after birth. Parameters, including bowel rate (number of bowel sounds per minute), frequency, and number of durations >2 s per min, were collected. Loess regression and derivative analysis were employed to characterize the dynamic progression of the bowel sound parameters relative to PMA, whereas Mann–Whitney U or Kruskal–Wallis H tests were utilized to assess between-group differences. Results: A nonlinear dynamic change was observed in the relationship between characteristic parameters of bowel sounds in preterm infants and PMA. A significant transition occurred at 33.1 weeks of PMA. The PMA groups showed a significant difference in both between-group and multiple comparisons ( P < 0.001). Conclusion: Bowel sound parameters demonstrated a nonlinear evolution with PMA, with an inflection point at 33.1 weeks that was synchronized with the critical maturation period of the enteric nervous system/interstitial cells of Cajal network. These parameters may serve as objective markers for assessing the dynamic maturation of the gastrointestinal system in preterm infants.
- 4 November 2026
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 14, 1728536
Open AccessNonlinear evolution of acoustic characteristics of bowel sounds in preterm infants
Introduction: Gastrointestinal function can be assessed through bowel sounds, which objectively indicate gastrointestinal movement. However, the conventional method of abdominal auscultation has considerable limitations. This study aimed to investigate the evolutionary patterns of acoustic characteristics of bowel sounds in preterm infants, explore their variation with postmenstrual ages (PMAs), and quantify the association between PMA and bowel sound maturity to characterize the developmental trajectory of intestinal motility in preterm infants. Methods: Twenty-seven preterm infants (gestational age: 30–36 + 6 weeks) were enrolled in this study. A convolutional neural network-based smart device was used to monitor bowel sounds 1–4 times weekly for ≥3 h from day 1 to 30 after birth. Parameters, including bowel rate (number of bowel sounds per minute), frequency, and number of durations >2 s per min, were collected. Loess regression and derivative analysis were employed to characterize the dynamic progression of the bowel sound parameters relative to PMA, whereas Mann–Whitney U or Kruskal–Wallis H tests were utilized to assess between-group differences. Results: A nonlinear dynamic change was observed in the relationship between characteristic parameters of bowel sounds in preterm infants and PMA. A significant transition occurred at 33.1 weeks of PMA. The PMA groups showed a significant difference in both between-group and multiple comparisons ( P < 0.001). Conclusion: Bowel sound parameters demonstrated a nonlinear evolution with PMA, with an inflection point at 33.1 weeks that was synchronized with the critical maturation period of the enteric nervous system/interstitial cells of Cajal network. These parameters may serve as objective markers for assessing the dynamic maturation of the gastrointestinal system in preterm infants.
- Open Access
- 29 June 2026
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 14, 1814184
Narrative review of human milk fortifiers for preterm infants
The advancements in perinatal medicine and neonatal intensive care have enhanced the survival rates of extremely preterm infants. Nevertheless, the incidence of extrauterine growth restriction persists at a relatively high level. As the optimal enteral feeding source for preterm infants, human milk alone may be unable to fulfill the high nutritional requirements of very preterm infants. Consequently, the supplementation of human milk with nutritional fortifiers has become a widely recognized practice. At present, diverse types of human milk fortifiers are employed in different enteral feeding situations for preterm infants. This article provides a descriptive review of the current use of various fortifiers and also introduces novel or investigational fortifiers.
- 29 June 2026
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 14, 1814184
Open AccessNarrative review of human milk fortifiers for preterm infants
The advancements in perinatal medicine and neonatal intensive care have enhanced the survival rates of extremely preterm infants. Nevertheless, the incidence of extrauterine growth restriction persists at a relatively high level. As the optimal enteral feeding source for preterm infants, human milk alone may be unable to fulfill the high nutritional requirements of very preterm infants. Consequently, the supplementation of human milk with nutritional fortifiers has become a widely recognized practice. At present, diverse types of human milk fortifiers are employed in different enteral feeding situations for preterm infants. This article provides a descriptive review of the current use of various fortifiers and also introduces novel or investigational fortifiers.
- Open Access
- 27 March 2026
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 13, 1711120
Early vitamin AD supplementation reduces transfusion needs in preterm infants: a retrospective cohort study
Introduction: Anemia of prematurity (AOP) is a common condition, often necessitating transfusion therapy. Although vitamin AD deficiency has been linked to anemia pathogenesis, the effect of supplementation timing on transfusion needs remains unclear. This study investigates the association between the initiation timing of vitamin AD supplementation and the number of transfusions received in preterm infants. Methods: In this retrospective cohort study, we included 226 preterm infants (gestational age 14 days), with propensity score matching applied to balance groups. Independent factors were identified using generalized linear models. Results: The timing of vitamin AD initiation was positively correlated with transfusion number [Spearman’s ρ = 0.200(0.068–0.326), p = 0.003], an association that remained significant in subgroups including infants 28–37 weeks and those without complications. Multivariable analysis identified supplementation timing as an independent risk factor for transfusion frequency [ β = 0.016(0.007–0.025), p < 0.001]. Segmented Poisson regression showed a significantly lower incidence rate ratio after supplementation [IRR = 0.139(0.098–0.199)]. The conditional Cox model revealed no immediate change in risk [ HR = 10.858(0.725–162.663), p = 0.084] but a significant time-dependent protective effect [ HR per log(day+1) = 0.381(0.160–0.911), p = 0.03], with the hazard ratio becoming protective by day 5 and reaching 0.32 (68% risk reduction) by day 28. After propensity score matching, no significant difference in transfusion frequency was found between the ≤14-day and >14-day groups [median (IQR): 2 (1.5–3) vs. 2 (2–4), p = 0.544]. Conclusion: This study suggests an association between earlier vitamin AD supplementation and reduced transfusion needs in preterm infants, supported by a time-dependent protective effect. The specific optimal timing requires further prospective investigation.
- 27 March 2026
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 13, 1711120
Open AccessEarly vitamin AD supplementation reduces transfusion needs in preterm infants: a retrospective cohort study
Introduction: Anemia of prematurity (AOP) is a common condition, often necessitating transfusion therapy. Although vitamin AD deficiency has been linked to anemia pathogenesis, the effect of supplementation timing on transfusion needs remains unclear. This study investigates the association between the initiation timing of vitamin AD supplementation and the number of transfusions received in preterm infants. Methods: In this retrospective cohort study, we included 226 preterm infants (gestational age 14 days), with propensity score matching applied to balance groups. Independent factors were identified using generalized linear models. Results: The timing of vitamin AD initiation was positively correlated with transfusion number [Spearman’s ρ = 0.200(0.068–0.326), p = 0.003], an association that remained significant in subgroups including infants 28–37 weeks and those without complications. Multivariable analysis identified supplementation timing as an independent risk factor for transfusion frequency [ β = 0.016(0.007–0.025), p < 0.001]. Segmented Poisson regression showed a significantly lower incidence rate ratio after supplementation [IRR = 0.139(0.098–0.199)]. The conditional Cox model revealed no immediate change in risk [ HR = 10.858(0.725–162.663), p = 0.084] but a significant time-dependent protective effect [ HR per log(day+1) = 0.381(0.160–0.911), p = 0.03], with the hazard ratio becoming protective by day 5 and reaching 0.32 (68% risk reduction) by day 28. After propensity score matching, no significant difference in transfusion frequency was found between the ≤14-day and >14-day groups [median (IQR): 2 (1.5–3) vs. 2 (2–4), p = 0.544]. Conclusion: This study suggests an association between earlier vitamin AD supplementation and reduced transfusion needs in preterm infants, supported by a time-dependent protective effect. The specific optimal timing requires further prospective investigation.
- Open Access
- 19 January 2026
- Published by Springer Nature in Pediatric Research
- p. 1-9
Bovine colostrum as a human milk fortifier for very preterm infants with slow feeding advancement: a randomized controlled trial
Background: Fortification of human milk for very preterm infants (VPIs) with alternatives to conventional bovine milk-based fortifiers remains minimally studied. This trial tested whether fortification with protein-rich bovine colostrum (BC) improves feeding intolerance and clinical variables in VPIs receiving enteral nutrition with a relatively slow advancement. Methods: In this unblinded, two-centre, randomised, controlled trial (FortiColos CN), VPIs (gestational age, 26 + 0 to 31 + 6 weeks) were fed human milk fortified with BC ( n = 74) or a conventional fortifier (CF, FM85, Nestlé, n = 72) for at least two weeks, starting when enteral feeding volume reached 80–100 mL/kg body weight/d. Incidence of feeding intolerance, nutrition intake, body growth, morbidities and clinical biochemical parameters were compared between the two groups. Results: No statistically significant difference was found in the incidence of feeding intolerance or in most of the nutritional or body growth parameters ( p > 0.05). All recorded morbidity incidences and haematological and blood biochemical parameters were also similar between groups. Amino acids (Phe, Pro, Ser, Tyr, Val) showed higher levels in the infants receiving BC. Conclusions: BC appeared safe when used as a fortifier to human milk for VPIs with slow feeding advancement, but did not improve feeding tolerance or clinical variables. Impact: Fortifying human milk with bovine colostrum (BC) in very preterm infants (VPIs) is safe but did not improve feeding tolerance, growth or clinical outcomes, compared with a conventional fortifier (CF), when used during slow enteral feeding advancement. This study adds to the limited clinical evidence on the use of BC as a human milk fortifier in VPIs receiving enteral feeding with different feeding protocols. The findings support the safety of BC as a human milk fortifier in VPIs but suggest limited short-term clinical benefits over currently used fortifiers.
- 19 January 2026
- Published by Springer Nature in Pediatric Research
- p. 1-9
Open AccessBovine colostrum as a human milk fortifier for very preterm infants with slow feeding advancement: a randomized controlled trial
Background: Fortification of human milk for very preterm infants (VPIs) with alternatives to conventional bovine milk-based fortifiers remains minimally studied. This trial tested whether fortification with protein-rich bovine colostrum (BC) improves feeding intolerance and clinical variables in VPIs receiving enteral nutrition with a relatively slow advancement. Methods: In this unblinded, two-centre, randomised, controlled trial (FortiColos CN), VPIs (gestational age, 26 + 0 to 31 + 6 weeks) were fed human milk fortified with BC ( n = 74) or a conventional fortifier (CF, FM85, Nestlé, n = 72) for at least two weeks, starting when enteral feeding volume reached 80–100 mL/kg body weight/d. Incidence of feeding intolerance, nutrition intake, body growth, morbidities and clinical biochemical parameters were compared between the two groups. Results: No statistically significant difference was found in the incidence of feeding intolerance or in most of the nutritional or body growth parameters ( p > 0.05). All recorded morbidity incidences and haematological and blood biochemical parameters were also similar between groups. Amino acids (Phe, Pro, Ser, Tyr, Val) showed higher levels in the infants receiving BC. Conclusions: BC appeared safe when used as a fortifier to human milk for VPIs with slow feeding advancement, but did not improve feeding tolerance or clinical variables. Impact: Fortifying human milk with bovine colostrum (BC) in very preterm infants (VPIs) is safe but did not improve feeding tolerance, growth or clinical outcomes, compared with a conventional fortifier (CF), when used during slow enteral feeding advancement. This study adds to the limited clinical evidence on the use of BC as a human milk fortifier in VPIs receiving enteral feeding with different feeding protocols. The findings support the safety of BC as a human milk fortifier in VPIs but suggest limited short-term clinical benefits over currently used fortifiers.
- Open Access
- 27 June 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (26) , e43100
Comparison of neonatal COVID-19 clinical features based on onset timing
The clinical features of neonatal sepsis that develop early and late differ, and it is unclear whether neonatal coronavirus disease 19 (COVID-19) varies depending on the day of onset. Based on whether the onset occurred within the first 5 days of life, all neonatal COVID-19 cases were divided into the early-onset group (EOG) and late-onset group (LOG). Clinical data of these cases diagnosed between December 14, 2022, and January 9, 2023, were gathered and analyzed retrospectively. Of the 212 neonates with COVID-19 included, 36 were in EOG and 176 were in EOG. The percentages of asymptomatic, mild, moderate, and severe cases were 9.4%, 76.9%, 11.3%, and 2.4%, respectively, and there were no critical cases. While 82.4% of mild cases and 15.4% of moderate or severe cases were in LOG, the EOG had a considerably larger proportion of asymptomatic infections (44.4% vs 2.3%) and only 1 moderate or severe case. The most common symptom (87.3%) was fever, which was more prevalent and lasted longer in LOG (93.8% vs 55.6%). The LOG also had higher rates of coughing (43.8% vs 5.6%) and poor appetite (70.5% vs 13.9%). Except for increased C-reactive protein in EOG and decreased white blood cells in LOG, there were no appreciable variations in liver enzymes, cardiac enzymes, or other infection biomarkers between the groups. Most pneumonia cases (96.8%) diagnosed by chest radiography occurred in LOG. Steroids and antiviral medications were not administered to any of infected infants, who only received symptomatic treatment. Five critical patients received neonatal intensive care. All the patients were cured and discharged. COVID-19 often manifests only weakly. Although the general prognosis was good for all groups, the LOG was more likely to experience fever, respiratory and gastrointestinal symptoms, and a small percentage of patients with moderate or severe disease.
- 27 June 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (26) , e43100
Open AccessComparison of neonatal COVID-19 clinical features based on onset timing
The clinical features of neonatal sepsis that develop early and late differ, and it is unclear whether neonatal coronavirus disease 19 (COVID-19) varies depending on the day of onset. Based on whether the onset occurred within the first 5 days of life, all neonatal COVID-19 cases were divided into the early-onset group (EOG) and late-onset group (LOG). Clinical data of these cases diagnosed between December 14, 2022, and January 9, 2023, were gathered and analyzed retrospectively. Of the 212 neonates with COVID-19 included, 36 were in EOG and 176 were in EOG. The percentages of asymptomatic, mild, moderate, and severe cases were 9.4%, 76.9%, 11.3%, and 2.4%, respectively, and there were no critical cases. While 82.4% of mild cases and 15.4% of moderate or severe cases were in LOG, the EOG had a considerably larger proportion of asymptomatic infections (44.4% vs 2.3%) and only 1 moderate or severe case. The most common symptom (87.3%) was fever, which was more prevalent and lasted longer in LOG (93.8% vs 55.6%). The LOG also had higher rates of coughing (43.8% vs 5.6%) and poor appetite (70.5% vs 13.9%). Except for increased C-reactive protein in EOG and decreased white blood cells in LOG, there were no appreciable variations in liver enzymes, cardiac enzymes, or other infection biomarkers between the groups. Most pneumonia cases (96.8%) diagnosed by chest radiography occurred in LOG. Steroids and antiviral medications were not administered to any of infected infants, who only received symptomatic treatment. Five critical patients received neonatal intensive care. All the patients were cured and discharged. COVID-19 often manifests only weakly. Although the general prognosis was good for all groups, the LOG was more likely to experience fever, respiratory and gastrointestinal symptoms, and a small percentage of patients with moderate or severe disease.
- Open Access
- 6 June 2025
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 13, 1596255
Osmolality of donor human milk rises dramatically within minutes of fortification with varied degrees depending on the fortifier used
Background: The addition of fortifiers to human milk can enhance its energy and protein content, although it results in an increase in osmolality, which may vary depending on the composition of fortifiers. The manner in which osmolality changes over time remains uncertain.Aims: We hypothesized that the impact of different fortifiers on osmolality would vary significantly and evolve dynamically with the duration of place time.Methods: Osmolality measurements were taken from the donor human milk (DHM)at 3 and 22 h after the addition of six different human milk fortifiers (HMFs) using a freezing osmolality meter. Furthermore, the osmolality was evaluated at nine time points following the standard fortification procedure with HMF1-3.Results: (1) The mean osmolality of the unfortified donor milk was 299 mOsm/kg. The addition of three multi-component fortifiers (HMF1-3) led to a significant elevation in osmolality (P < 0.05), albeit to varying extents (54.6–109.1 mOsm/kg). The addition of the preterm formula HMF4 resulted in a lesser increase in osmolality in comparison to HMF1 and HMF2. (2) The osmolality increased significantly by 183.0 ± 27.4 mOsm/kg after the addition of the protein fortifier PF1, whereas it increased by only 8.9 ± 2.9 mOsm/kg after the addition of PF2 (P < 0.05). (3) The osmolality at 22 h showed a minimal increase of 0.3–3.7 mOsm/kg (0.1%–1.0%) compared to the osmolality at 3 h following the addition of the six fortifiers. (4) The increase in osmolality following fortification with HMF1-3 was predominantly observed within two minutes of addition, accounting for 85.9%–91.2% of the total increase, followed by a slow increase over the subsequent 12 h, with a slight decrease thereafter.Conclusions: The addition of fortifiers significantly increased the osmolality of DHM. However, the degree of increase varied depending on the nutrient composition and content of the fortifiers used. It remains a challenge to avoid the rapid increase in osmolality of DHM within a very short time after the addition of a fortifier, even when fortifying at the bedside.
- 6 June 2025
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 13, 1596255
Open AccessOsmolality of donor human milk rises dramatically within minutes of fortification with varied degrees depending on the fortifier used
Background: The addition of fortifiers to human milk can enhance its energy and protein content, although it results in an increase in osmolality, which may vary depending on the composition of fortifiers. The manner in which osmolality changes over time remains uncertain.Aims: We hypothesized that the impact of different fortifiers on osmolality would vary significantly and evolve dynamically with the duration of place time.Methods: Osmolality measurements were taken from the donor human milk (DHM)at 3 and 22 h after the addition of six different human milk fortifiers (HMFs) using a freezing osmolality meter. Furthermore, the osmolality was evaluated at nine time points following the standard fortification procedure with HMF1-3.Results: (1) The mean osmolality of the unfortified donor milk was 299 mOsm/kg. The addition of three multi-component fortifiers (HMF1-3) led to a significant elevation in osmolality (P < 0.05), albeit to varying extents (54.6–109.1 mOsm/kg). The addition of the preterm formula HMF4 resulted in a lesser increase in osmolality in comparison to HMF1 and HMF2. (2) The osmolality increased significantly by 183.0 ± 27.4 mOsm/kg after the addition of the protein fortifier PF1, whereas it increased by only 8.9 ± 2.9 mOsm/kg after the addition of PF2 (P < 0.05). (3) The osmolality at 22 h showed a minimal increase of 0.3–3.7 mOsm/kg (0.1%–1.0%) compared to the osmolality at 3 h following the addition of the six fortifiers. (4) The increase in osmolality following fortification with HMF1-3 was predominantly observed within two minutes of addition, accounting for 85.9%–91.2% of the total increase, followed by a slow increase over the subsequent 12 h, with a slight decrease thereafter.Conclusions: The addition of fortifiers significantly increased the osmolality of DHM. However, the degree of increase varied depending on the nutrient composition and content of the fortifiers used. It remains a challenge to avoid the rapid increase in osmolality of DHM within a very short time after the addition of a fortifier, even when fortifying at the bedside.
- Open Access
- 19 May 2025
- Published by Springer Nature in BMC Pediatrics
- Vol. 25 (1) , 1-7
Neonatal Jka hemolytic disease combined with alloimmune thrombocytopenia with extreme anemia: a case report with literature review
Only isolated occurrences of neonatal Jka hemolytic disease have been identified, and no cases of Jka hemolytic disease combining fetal and neonatal alloimmune thrombocytopenia (FNAIT) have been reported. The majority of medical professionals lack sufficient knowledge regarding Jka hemolytic disease, which could result in missed diagnoses and early misdiagnoses. In this study, a case of a male newborn with extreme anemia and thrombocytopenia is reported. The newborn and his mother were identified as blood groups O RhD + and Jk(a + b+), and O RhD + and Jk(a-b+). Anti-Jka was identified in the plasma of both the mother and newborn. Thrombocytopenia and upper gastrointestinal bleeding were observed in the newborn, and both mother and newborn tested positive for platelet antibodies. The extreme anemia and thrombocytopenia were successfully treated with red cell transfusions and immunoglobulin. Co-existence of neonatal Jka hemolytic disease and FNAIT is very rare in newborns with significant clinical manifestations. Early diagnosis and timely treatment are crucial for improving patient outcomes.
- 19 May 2025
- Published by Springer Nature in BMC Pediatrics
- Vol. 25 (1) , 1-7
Open AccessNeonatal Jka hemolytic disease combined with alloimmune thrombocytopenia with extreme anemia: a case report with literature review
Only isolated occurrences of neonatal Jka hemolytic disease have been identified, and no cases of Jka hemolytic disease combining fetal and neonatal alloimmune thrombocytopenia (FNAIT) have been reported. The majority of medical professionals lack sufficient knowledge regarding Jka hemolytic disease, which could result in missed diagnoses and early misdiagnoses. In this study, a case of a male newborn with extreme anemia and thrombocytopenia is reported. The newborn and his mother were identified as blood groups O RhD + and Jk(a + b+), and O RhD + and Jk(a-b+). Anti-Jka was identified in the plasma of both the mother and newborn. Thrombocytopenia and upper gastrointestinal bleeding were observed in the newborn, and both mother and newborn tested positive for platelet antibodies. The extreme anemia and thrombocytopenia were successfully treated with red cell transfusions and immunoglobulin. Co-existence of neonatal Jka hemolytic disease and FNAIT is very rare in newborns with significant clinical manifestations. Early diagnosis and timely treatment are crucial for improving patient outcomes.
- Open Access
Identification of serum metabolite biomarkers in premature infants with bronchopulmonary dysplasia: protocol for a multicentre prospective observational cohort study
Introduction Bronchopulmonary dysplasia (BPD) is one of the most common and significant complications of preterm birth. It ultimately leads to a decrease in the quality of life for preterm infants and impacts their long-term health. Early prediction and timely intervention are crucial to halting the development of BPD. This study aims to identify the biomarkers that can predict the early occurrence and development of BPD by screening serum metabolites in preterm infants. This will provide strong support for the early prediction of BPD and targeted interventions in future research. Methods and analysis This is a prospective, multicentre, open-label, observational cohort study spanning 3 years. It will be conducted in six major neonatal intensive care units in Shenzhen, China, involving preterm infants born at gestational ages Ethics and dissemination Our protocol has been approved by the Medical Ethics Committees of all participating hospitals, including Peking University Shenzhen Hospital, Shenzhen People’s Hospital, Shenzhen Baoan Women’s and Children’s Hospital, Longgang District Maternity and Child Healthcare Hospital, Nanshan Maternity and Child Healthcare Hospital and Shenzhen Luohu People’s Hospital. We will disseminate our study results through academic conferences and peer-reviewed public journals. Trial registration number ChiCTR2400081615.
Open AccessIdentification of serum metabolite biomarkers in premature infants with bronchopulmonary dysplasia: protocol for a multicentre prospective observational cohort study
Introduction Bronchopulmonary dysplasia (BPD) is one of the most common and significant complications of preterm birth. It ultimately leads to a decrease in the quality of life for preterm infants and impacts their long-term health. Early prediction and timely intervention are crucial to halting the development of BPD. This study aims to identify the biomarkers that can predict the early occurrence and development of BPD by screening serum metabolites in preterm infants. This will provide strong support for the early prediction of BPD and targeted interventions in future research. Methods and analysis This is a prospective, multicentre, open-label, observational cohort study spanning 3 years. It will be conducted in six major neonatal intensive care units in Shenzhen, China, involving preterm infants born at gestational ages Ethics and dissemination Our protocol has been approved by the Medical Ethics Committees of all participating hospitals, including Peking University Shenzhen Hospital, Shenzhen People’s Hospital, Shenzhen Baoan Women’s and Children’s Hospital, Longgang District Maternity and Child Healthcare Hospital, Nanshan Maternity and Child Healthcare Hospital and Shenzhen Luohu People’s Hospital. We will disseminate our study results through academic conferences and peer-reviewed public journals. Trial registration number ChiCTR2400081615.
- Open Access
- 28 November 2024
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 12, 1466528
Narrative review of methodological advances in human milk fortification: for better preterm infant growth
It is generally suggested that human milk alone might not be enough to meet the nutritional requirements of very preterm infants, necessitating the use of nutritional fortification. The composition of human milk varies among individuals and changes over time, challenging the assumption that protein content and energy density remain constant during standard fortification. Consequently, it has led to suboptimal body growth rates in most very preterm infants compared to fetuses of the same gestational age. In light of this, personalized fortification and innovative fortification strategies have been introduced. This paper aims to review the importance of fortification and the shortcomings of standard fortification, as well as describe and evaluate the advantages and limitations of various individualized fortifications. The optimal use of human milk fortification, in accordance with the nutrient content of human milk and the physiological maturity and growth of preterm infants, is a crucial aspect of the field of preterm infant nutrition.
- 28 November 2024
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 12, 1466528
Open AccessNarrative review of methodological advances in human milk fortification: for better preterm infant growth
It is generally suggested that human milk alone might not be enough to meet the nutritional requirements of very preterm infants, necessitating the use of nutritional fortification. The composition of human milk varies among individuals and changes over time, challenging the assumption that protein content and energy density remain constant during standard fortification. Consequently, it has led to suboptimal body growth rates in most very preterm infants compared to fetuses of the same gestational age. In light of this, personalized fortification and innovative fortification strategies have been introduced. This paper aims to review the importance of fortification and the shortcomings of standard fortification, as well as describe and evaluate the advantages and limitations of various individualized fortifications. The optimal use of human milk fortification, in accordance with the nutrient content of human milk and the physiological maturity and growth of preterm infants, is a crucial aspect of the field of preterm infant nutrition.
- Open Access
Multicentre online registration of bronchopulmonary dysplasia in very preterm infants in China: protocol for a prospective, open, observational cohort study
Introduction Bronchopulmonary dysplasia (BPD) in very preterm infants (VPIs) has adverse long-term outcomes and affects the quality of survival. There are no registry studies on BPD in VPIs in China. Our aim was to conduct a prospective, multicentre, open, longitudinal, observational cohort study to investigate the epidemiological characteristics, diagnosis, treatment, and short-term and long-term outcomes of BPD in a real-life setting in China and lay the grounds for establishing a nationwide registry with clinical data and biological specimens. Methods This study aims to recruit a minimum of 2000 VPIs and start research in January 2024 in Shenzhen, China. We will collect clinical data from the beginning of the life of VPIs and follow them up to 3 years old. Short-term outcomes, such as the incidence of BPD, necrotising enterocolitis, retinopathy of prematurity, intraventricular haemorrhage and porencephalic ventricular leukomalacia, as well as the cost of hospitalisation, are the major variables of concern. Bayley-III Scale assessment, gross motor function and pulmonary function evaluation will be performed at the age of correction, that is, 18–24 months and 30–36 months. The follow-up outcomes include loss to follow-up, survival status, moderate-to-severe neurodevelopmental deficits and severe respiratory complications. Cord blood, peripheral blood, tracheal aspirate, faeces and urine from VPIs, as well as mother’s milk, will be collected and stored at −80°C. All the data will be registered, stored and managed in a cloud-based database. This knowledge will be useful for establishing diagnostic criteria and predictive models for BPD in the Chinese population. Ethics and dissemination Our protocol has been approved by the Medical Ethics Committee of Shenzhen People’s Hospital (LL-KY-2023174-02) and the local ethics committee of each participating centre. Our goal is to present our findings at national conferences and in peer-reviewed paediatric journals. Trial registration number Chinese Clinical Trial Registry (ChiCTR2400081615).
Open AccessMulticentre online registration of bronchopulmonary dysplasia in very preterm infants in China: protocol for a prospective, open, observational cohort study
Introduction Bronchopulmonary dysplasia (BPD) in very preterm infants (VPIs) has adverse long-term outcomes and affects the quality of survival. There are no registry studies on BPD in VPIs in China. Our aim was to conduct a prospective, multicentre, open, longitudinal, observational cohort study to investigate the epidemiological characteristics, diagnosis, treatment, and short-term and long-term outcomes of BPD in a real-life setting in China and lay the grounds for establishing a nationwide registry with clinical data and biological specimens. Methods This study aims to recruit a minimum of 2000 VPIs and start research in January 2024 in Shenzhen, China. We will collect clinical data from the beginning of the life of VPIs and follow them up to 3 years old. Short-term outcomes, such as the incidence of BPD, necrotising enterocolitis, retinopathy of prematurity, intraventricular haemorrhage and porencephalic ventricular leukomalacia, as well as the cost of hospitalisation, are the major variables of concern. Bayley-III Scale assessment, gross motor function and pulmonary function evaluation will be performed at the age of correction, that is, 18–24 months and 30–36 months. The follow-up outcomes include loss to follow-up, survival status, moderate-to-severe neurodevelopmental deficits and severe respiratory complications. Cord blood, peripheral blood, tracheal aspirate, faeces and urine from VPIs, as well as mother’s milk, will be collected and stored at −80°C. All the data will be registered, stored and managed in a cloud-based database. This knowledge will be useful for establishing diagnostic criteria and predictive models for BPD in the Chinese population. Ethics and dissemination Our protocol has been approved by the Medical Ethics Committee of Shenzhen People’s Hospital (LL-KY-2023174-02) and the local ethics committee of each participating centre. Our goal is to present our findings at national conferences and in peer-reviewed paediatric journals. Trial registration number Chinese Clinical Trial Registry (ChiCTR2400081615).